XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) č. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx xxxxxxxx systematického xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx obsažených x xxxxxxxxxx xxxxxxxxxxx, xxxxx xxxx uvedeny v xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (EU) č. 528/2012
(Xxxx x významem xxx XXX)
XXXXXXXX XXXXXX,
s ohledem xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x ohledem xx xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. xxxxxx 2012 o dodávání xxxxxxxxxx xxxxxxxxx na xxx x jejich xxxxxxxxx (1), x zejména xx čl. 89 xxxx. 1 první xxxxxxxxxxx xxxxxxxxx nařízení,
xxxxxxxx x těmto důvodům:
|
(1) |
Nařízení Xxxxxx (ES) x. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx xxxxxxx xxxxxxxx xxxxxxxxxxx biocidních xxxxxxxx xxxxx (xxxx jen „xxxxxxx xxxxxxxx“), xxxxx xxx xxxxxxx x xxxxxxx x xx. 16 odst. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx byla zrušena x xxxxxxxxx xxxxxxxxx (XX) x. 528/2012, měla xx xxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx ustanovením xxxxxxxxx nařízení. |
|
(2) |
Xx xxxxxxxx xxxxx kombinace účinné xxxxx x xxxx xxxxxxxxx, které xxxxx xxx dodávány na trh x xxxxxxxxx xxxxx přechodných xxxxxxxxxx xxxxxx 89 nařízení (XX) č. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx. Xxxx xx tomu být x v xxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, xxxxx jsou xxxxxxxxx x xxxxxxxx xxxxxxxx. |
|
(3) |
Pokud xxxxxxxxx využíval odchylky xxx xxxxxxxxx x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (ES) x. 1451/2007, xxx nevztahuje xx xx xxx xxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) nařízení (XX) x. 528/2012, měly xx xxx xxxxxx xxxxx, xxxxx obsahuje, hodnoceny x xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx přípravku. X xxxxxxxx vnitrostátních předpisů xx mělo xxx xxxxxx dodávání xx xxx x xxxxxxxxx umožněno xx xx xxxxxxxx uvedeného xxxxxxxxx. Xxxxxx předchozího xxxxxxxxxx xx xxx xxxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxxxx využijí. Totéž xx mělo xxxxxx x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx vyplynulo x xxxx xxxxxxxx xxxx xxxxxxxxx x xxxxxxxx (XX) č. 528/2012 xxxxxx xxxxxxxx xxxxxxx ve xxxxxxxx 98/8/ES xxxx xx xxxxx odůvodněno xxxxxxxxxxx Xxxxxx přijatým x xxxxxxx s čl. 3 odst. 3 xxxxxxxx (EU) x. 528/2012, xxxxxxxxxxx (xxxxxxxxx xxxxxxxxxxx xx xxxx X-420/10 (4)) xxxx xxxxxxxxx xxxxxx Xxxxxx či xxxxxxxxxxx xxxxxx členských xxxxx, xxxxx xx xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx, xxxxx xxx xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, z xxxx xxxxx xxxxxxx xxxx xx x ní xxxxxx, xxxxx xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx přípravku x xxxxxxxx xxxxx xxxxxxxx, xxxx xx být v tomto xxxxxxxx xxxxx použití x xxxxxxxx xx xxx xxxxxxxx na xxxx xxxxxxxxxxxx, za určitých xxxxxxxx x xx xxxxxxxx xxxx. |
|
(5) |
X xxxxx xxxxxxxxxxx x xxxxxxxxxxxx by xxx xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 nařízení (XX) č. 528/2012 nebo xxxxx prováděcího xxxxxxxx Xxxxxx (XX) x. 88/2014 (5). |
|
(6) |
Pro xxxxx, xxxxx splňují xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx xxxxxxx, xx xxx xxxxxxxxx xxxxxxxxx orgán předložit xxxxxxxx návrh xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxx xxxxx xx. 37 odst. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) č. 1272/2008 (6), xxxxx xxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx xx xxxx xxx zachováno xxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxx xx xxxxxx xxxx xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxxx xxxxxxxx v xxxxxxx látek, xxxxx xx xxxxxxxxx xxxxxxxx xxx xxxxx perzistentní, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, xxxxx xx xxxxx xxx považovány xx látky x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
|
(7) |
Xxx xxxx xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx xx xxxxxxxx data xxxxxxxxx x xx. 89 xxxx. 1 xxxxxxxx (XX) x. 528/2012, mělo xx xx hodnocení xxxxxx na kombinace xxxxxx látky x xxxx xxxxxxxxx, u xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxx stanovených x xxxxxxxx (XX) x. 1451/2007 xxxx x xxxxx xxxxxxxx. Xxxxx xxxx xx xx xxxx xxxxxxxx xxxxxx lhůty xxx xxxxxxxxx hodnocení, xxxxxxx xx se měla xxxx x úvahu xxxxxxx, xx žádosti xx mohly xxx xxxxxxxxx méně než xxx xxxx xxxxxxxxx xxxxxx xxxx. |
|
(8) |
Xxxxxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx 7 nařízení (XX) č. 528/2012 dosud xxxxxx stanoveny xxxxx xxxxxxxxx xx údaje. Xx xxxxx vhodné x této fázi xxxxxx žádosti x xxxxxxxx xx xxxxxxx přílohy xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6. |
|
(9) |
Bez xxxxxx na čl. 90 xxxx. 2 xxxxxxxx (EU) č. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx uvedená v článku 10 xxxxxxxxx nařízení by xxxx xxx relevantní xxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Xx proto xxxxxx určit xxxxx xxxxxxxxx xxxx xxxxxxxx xx xxxxx hodnoceních xxxxxxxx xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xx měl xxx možnost xx xx xxxxxxxx xxxxxx xxxxxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxx jej xxxxxxxx za předpokladu, xx xxxxx xxxx xxxxxxx xx zpoždění xxxxxxxxx x xxxxxx xxxxxxxxx xxxxxxxx x xxxxxx, xxxxxxx jinak xx xxxxxxxxxxx xxxxxxxx musel xxxxxxxxx xxxxx znovu. |
|
(11) |
Xxxxxxx xx xxxxx v programu xxxxxxxx dobrovolná, xxxx xx xxx xxxxxxxxxx xxxxxxxx xx xx xxxxxxxxx. Xxxxx x xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxxxx, nebylo-li této xxxxxxxx xxxxxxx již xxxxxx, xxxxx xxx xxxxxxx ke xxxxxxxx xxxxxxxx přezkumu, x xxxxxxxx-xx xxxxxxxx xxx xxxxxxxx na svém xxxxxxxxxx. |
|
(12) |
Xxxxx xx xxx xxxxxxxxx účinné látky xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx do programu přezkumu xxxxxx neodpovídá identitě xxxxxxxx xxxxxxxxx látky, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, xxxx xx xxx xxxxx xxxx xxxxx x xxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a povolit xxxxx xxxxxx, aby xxxxxxxx podporu xxxx xxxxxxxxx zařazené látky. |
|
(13) |
Xxxxxxx xxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxxx x xxxx xxxxxxx xxxxxx xxxxxxxx podporovány xxxxxx xxxxxxxxxx. Xxxxx xx týká určitých xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 odst. 4 xxxxxxxx (XX) č. 528/2012 xxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxx není xxxxxxxx stanoveno. X xxxxxxxxx látek a xxxxxxxxxxxxx xx xxxx xxx xxxxx xxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xx xxxx xxxxx a nanomateriály xxxxxx xxx x xxxxxxxx xxxxxxxx xxxxxxxxx. |
|
(14) |
Xxx xxxx xxxxxxxxx, že žádná xxxxx xxxxxxxxx v xxxxxxxx xxxxxxxxxxx xxx xx xxx xxxxxx xxxxxxxx, xxxx xx xxxxxxxx xxxx xxxxxxxxxxx, xxxx xx xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx hodnocena, x xxxxxxxx xxxx její xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx x xx, |
XXXXXXX TOTO XXXXXXXX:
XXXXXXXX 1
XXXXXXX X XXXXXXXX
Xxxxxx 1
Předmět
Toto nařízení xxxxxxx pravidla pro xxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 nařízení (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Xxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx xxxx xxxxxxxx:
|
x) |
„xxxxxxxxxxx x xxxxxxxxxxx“ se xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx látky a typu xxxxxxxxx podle čl. 9 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012 xxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx uvedeného xxxxxxxx, xxxx xxxxxxxxx xxxxxxxxx xx xxxxxxx X xxxx XX xxxxxxxx 98/8/XX; |
|
b) |
„xxxxxxxxx xxxxx x xxxx xxxxxxxxx zařazenou xx xxxxxxxx přezkumu“ xx xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx XX, která xxxxxxx xxxx xxxxxxxx:
|
|
x) |
„účastníkem“ xx xxxxxx xxxxx, xxxxx xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxx do programu xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, xxxxx odpovídá xxxxxxxxxx xxxxx xx. 17 xxxx. 5 tohoto xxxxxxxx, xxxx xxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxx předloženo; |
|
d) |
„hodnotícím xxxxxxxxxx xxxxxxx“ xx xxxxxx příslušný orgán xxxxxxxxx státu xxxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, určený x xxxxxxx x xxxxxxx 81 nařízení (XX) x. 528/2012. |
XXXXXXXX 2
XXXXXX XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxx X xxxxxxxx (XX) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx či xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) č. 528/2012 xxxx xxxxx xxxxx xxxxxxxx, x xxxxx oznámení xxxxx xxxxxxxx k xxxxxx, že odpovídá xxxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5 tohoto xxxxxxxx.
Xxxxx xx xxxxxx týká xxxxxxxx do přílohy I nařízení (XX) x.&xxxx;528/2012, xxxx xx týkat xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené x&xxxx;xxxxxxxx 1 xx xxxxxxxx xxxxxxxx xx&xxxx;xxxx xxx xx xxxxxxxxxx x&xxxx;xxxxxxx x xxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Přijetí žádostí
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx o xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx nařízení Komise (XX) x. 564/2013 (7) x xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx i xxxxxxxxx xxxxxxxxx xxxxx.
2. Po xxxxxxxx xxxxxxxx xxxxxxxxx podle xxxxxxxxxxx xxxxxxxx (XX) x. 564/2013 xxxxxx xxxxxxxx xxxxxx x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx orgán, xxxxxxx uvede xxxxx xxxxxxx žádosti x xxxx xxxxxxxxx xxxxxxxxxxxxx kód.
3. Proti xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 1 xxxxxx xxxxxx lze xxxxx xxxxxxx xxxxxxxxxx v xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012.
4. Hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx splatném xxxxx čl. 80 xxxx. 2 xxxxxxxx (XX) č. 528/2012 xx 30 xxx xxxx, co agentura xxxxxxx xxxxxx, x xxxxxxx xxxxxx, pokud xxxxxxxx nezaplatí poplatek xx xxxxx 30 xxx. X této xxxxxxxxxxx informuje účastníka x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx žádostí x schválení xxxx xxxxxxxx do xxxxxxxxx 6 přílohy X xxxxxxxx (XX) x. 528/2012
1. Xxxxx xxxxxxxx xxxxxx xxxxx xx. 4 xxxx. 2 žádost x xxxxxxxxx nebo zařazení xx xxxxxxxxx 6 přílohy X xxxxxxxx (XX) x. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxx x xx. 6 xxxx. 1 a 2 xxxxxxxxx xxxxxxxx, x xxx xxxxxxxx xxxxxxxx xxxxx xx. 4 odst. 4, xxxxxxxxx xxxxxxxxx orgán xxxxxx xxxxxxx do 30 xxx xx zaplacení xxxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxxx od účastníka xxxxxxxxxxx xxxxx xxxxxxxx (XX) x. 1451/2007, avšak xx xxxxx xxxxxx xxxxxx xxxx xxxxx xxxxx xxxxxx 13 xxxxxxxxx xxxxxxxx, potvrdí xxxxxxxxx xxxxxxxxx orgán žádost xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x odstavcích 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx kvality xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxx.
4. Xxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx žádost xx xxxxxxx, xxxxx účastníkovi, xxxx doplňující xxxxxxxxx xxxx k xxxxxxxxx xxxxxxx xxxxx, x x xxxxxxxxxx xxxxxx xxxxxxxxx stanoví xxxxxxxxxx xxxxx. Xxxx xxxxx xxxxx xxxxxxxxxx 90 xxx.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx předložené doplňující xxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx 2, xxxxxxx žádost xx 30 xxx xx xxxxxxxx xxxxxxxxxxxx informací.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx žádost xxxxxxx x xxxxxxxxx o xxxx xxxxxxxxxxx xxxxxxxxx x agenturu. X xxxxxx xxxxxxxxx xx xxxxx xxxxxxxx zaplacené x xxxxxxx x xx. 80 xxxx. 1 x 2 xxxxxxxx (EU) x. 528/2012.
Xxx potvrzení xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx příslušné xxxxxx x xxxxx datum xxxxxx xxxxxxxxx.
Xxxxxx 6
Hodnocení žádostí
1. Xxxxx xxxxxx xx použije, xxxxx platí některá x xxxxxx xxxxxxxx:
|
x) |
xx-xx xxxxxx xxxxxxxxx xxxxx xxxxxx 5; |
|
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx uznal xxxxxxxxxxx xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (ES) x. 1451/2007, ale xxxxx xxxxxxxxxxx Xxxxxx zprávu xxxxxxxxxxx xxxxxx xxxxx xx. 14 xxxx. 4 xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxx agentura xxxxxxx xxxxxx x zařazení xx xxxxxxxxx 1, 2, 3, 4 nebo 5 xxxxxxx I nařízení (XX) x. 528/2012 xxxxx xx. 4 xxxx. 2 x xxx zaplacen xxxxxxxx xxxxx xx. 4 xxxx. 4. |
2. Xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxx veškeré xxxxxx xx xxxxxx xxxxxxxxx xx xxxxx předložené x xxxxxxx x xx. 6 odst. 3 uvedeného nařízení x zašle hodnotící xxxxxx x závěry xxxxx xxxxxxxxx xxxxxxxx.
3. Pokud xxxxxxx xxxxxxxxx xxxxx x xxxx přípravků xxxxxxxxx několik xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx pouze xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx x xxxxxx xxxxx x xxxxx z těchto xxxx, xxxxx toho, xx xxxxxxx později:
|
x) |
365 xxx po posledním xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), uznání xxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x) xxxx zaplacení xxxxxxxx xxxxxxxxx v odst. 1 xxxx. x) x xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx; |
|
b) |
ve xxxxx xxxxxxxxx v příloze XXX. |
4. Xxxx tím, než xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxx xxxxxx xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx do 30 xxx x hodnotící xxxxxx a x xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx tyto xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxx xxxxx xxxxxxxxx.
5. Xxxxx se xxxxx, xx xxxx x xxxxxxxxx nutné xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx účastníka xxxxx, xxx xxxx xxxxxxxxx xx stanovené xxxxx xxxxxxxxx, x xxxxxxxxx x xxx xxxxxxxx.
Xxxxx 365 xxx xxxxxxx v odstavci 3 xx xxxxxxx xx xxxx xxx xxx xxxxxxxx požadavku xx xxx xxxxxxxx xxxxxxxxx. Xxxxx xx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx údajů xxxx xxxxxxxxxxx okolnostmi, xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx lhůty:
|
x) |
365 xxx x xxxxxxx, xx xx xxxxxxxxxx informace xxxxxx xxxxxx, xxxxx xxxxxx řešeny x xxxxx směrnice 98/8/XX xxxx x xxxxx postupů xxxxxxxxxxx xxx xxxxxxxxxxx xxxxxxx xxxxxxxx; |
|
b) |
180 xxx xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Xxxxx xxxxxxxxx příslušný orgán xxxxxx, že existují xxxxx xxxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxxx xxxxxxxxx vyplývající x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx biocidních xxxxxxxxx xxxxxxxxxxxx stejné xxxx xxxxxxxx xxxxxx xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxx oddílu II xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 (8) a zahrne xx xx xxxxx xxxxxx.
7. X případě xxxxxxx xx dokončení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx příslušný xxxxx bez xxxxxxxxxx xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx hodnotící xxxxxx xxxxx xxxxxxxx 3:
|
a) |
xxxxxxxx xxxxx xxxxxxxx podle xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, jestliže xx xxxxxxx, xx xx xxxxxxx jedno x xxxxxxxx xxxxxxxxx x xx. 36 odst. 1 xxxxxxxxx xxxxxxxx, ale xxxx xxxxxxxx xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
|
b) |
konzultuje x xxxxxxxxx, xxxxx se xxxxxxx, xx xxxxx x xxxxxxxx xx. 5 xxxx. 1 xxxx. x) xxxx x) nařízení (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx xxxxxxxx jsou xxxxxxx, xxx xxxxxx xxxxxxxx xxxxxx v příloze XXX nařízení (XX) x. 1907/2006 nebo x xxxxxxx xxxxxxxx v čl. 59 xxxx. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
x) |
pokud xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx zprávu podle xx. 6 xxxx. 2 x xxxxxxxx předložil xxxxx xxxx provedl konzultaci xxxxx xx. 6 xxxx. 7; |
|
b) |
xxxxx xxxx předložena Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx čl. 14 xxxx. 4 xxxxxxxx (XX) x. 1451/2007, xxx xxxxxxxxx zprávu xxxxx nepřezkoumal Stálý xxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xx. 15 xxxx. 4 uvedeného xxxxxxxx. |
2. Po xxxxxxx xxxxxx xxxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, s ohledem xx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxxx zahájí xxxxxxxx xxxxxxxxxx x xxxxx x xxxxxx xxxx, podle toho, xx xxxxxxx xxxxxxx:
|
x) |
do xxx měsíců po xxxxxxx xxxxxx; |
|
x) |
ve xxxxx xxxxxxxxx x xxxxxxx XXX. |
Xxxxxxxx xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné látky, xxxxx xx xxxx xxxxxxxx
1. Xxx xxxxxxxx svého xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxxxxxx xxxxxxx, xxx účinná xxxxx xxxxxxx některé x xxxxxxxx xxxxxxxxx x xx. 10 odst. 1 xxxxxxxx (XX) x. 528/2012, x xxxx xxxxxx xxxxx xx xxxx stanovisku.
2. Xxxx xxxx xxxxxxx xxxxxx 66 x 67 nařízení (XX) x. 528/2012, dříve xxx xxxxxxxx xxxxxxxx xxx xxxxxxxxxx Komisi, xxxxxxxx xxxxxxxxx x xxxxxxx látkách, xxxxx se xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; x xxxx době xxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx informace xxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx. Agentura obdržené xxxxxxxxx xxxxxxxx xxxxxxxx x závěrečné xxxx xxxxxxxx svého xxxxxxxxxx.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxx x xxxxxxxx stanovených x xx. 10 xxxx. 1 nařízení (XX) x. 528/2012, xxxx xxx xxxxxxxx xx látku, xxxxx xx xx xxxxxxxx, v nařízení xxxxxxxx x xxxxxxx s čl. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Po xxxxxxxx stanoviska agentury xxxxx čl. 7 odst. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx připraví návrh xxxxxxxxxx pro xxxxxxx xxxxx xx. 89 xxxx. 1, xxxx xxxxxxxx xxxxx xx. 28 odst. 1 xxxxxxxx (XX) x. 528/2012.
KAPITOLA 3
ZMĚNY XXXXX XXXXXXXX PŘEZKUMU
Článek 10
Xxxxxxxxx xxxx nahrazení účastníků xx vzájemné xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx xx xxxxx xx xxxxxxxx dohodě xxxx xxxxxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xx předpokladu, že xx xxxxxxxxxxx účastník xxxxx odvolávat xx xx xxxxxxx xxxxx xxxxxxxxxx nebo xxxxxxx xxxxxxxxxx účastníkem.
2. Oznámení xxx xxxxx tohoto xxxxxx xxxxxxxxxxx agentuře společně xxxxxxxxxxx a stávající xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxxxxxx x článku 71 xxxxxxxx (EU) č. 528/2012 (xxxx jen „xxxxxxxx“) x&xxxx;xxxxxxxx musí xxxxxxxxx všechna příslušná xxxxxxxx k přístupu.
3. Po xxxxxxxx xxxxxxxx splňujícího xxxxxxxxx xxxxx odstavce 2 xxxxxxxx aktualizuje xxxxxxxxx x&xxxx;xxxxxxxxx týkající xx xxxxxxxxxx účastníka.
4. Osoba xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx xxxxxxxx roli xxxxxxxxx nebo se xxxxxxxxx x účastníkovi xxxxx xxxxxx článku, xx pro xxxxx xxxxxx 95 nařízení (XX) č. 528/2012 xxxxxxxxxx xx xxxxx, xxxxx xxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Xxxxxxxxxx xxxxxxxxx
1. Má xx xx to, xx účastník xxxxxxxxx x účasti xx xxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx v programu xxxxxxxx, x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxxxx agenturu xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx xxxxxx xxxxxxxxx; |
|
x) |
xxxxx xxxxxxxxxxx žádost xx xxxxx xxxxxxx x xx. 3 xxxx. 2; |
|
x) |
pokud xxxx xxxxxx byla xxxxxxxxx xxxxx čl. 4 xxxx. 1, xx. 4 xxxx. 4 nebo xx. 5 xxxx. 4; |
|
d) |
pokud xxxxxxxxxxx xxxxxxxxxx informace xx xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx xxxx xxxxxxxx. |
2. Xxxxxxxxxx xx považuje xx xxxxxxxxx xxxx, xxxxx x němu xxxxxxx xx xxxx, kdy xxxxxxxxx příslušný xxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 6 odst. 4 tohoto xxxxxxxx.
Xxxxxx 12
Xxxxxxxx xxxxxxxx xxxxxxxxxx
1. Xxxxx xx o xxxxxxx odstoupení xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx xxxxxx xxxxxxxx, xxxxxxxxx xx xxxxxxxxx xxxxxxxxx orgán xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx je x xxxxxxx odstoupení xxxxxxxxxxx xxxxxxxx, aktualizuje xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx byla xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx o xxx xxxxxxxx prostřednictvím rejstříku Xxxxxx.
Xxxxxx 13
Nová xxxxxxxx xxxxxxxxx xxxxx
1. Xxxxx xxxxxxxxx xxxxxxxxx xxxxxx látky xxxxxxxx xxxxxxx závěry xxxxxxxx xx xxxxx, xxx xxxx uvedeny x xxxxxxx XX, hodnotící xxxxxxxxx xxxxx po xxxxxxxxxx x xxxxxxxx účastníkem xxxxxxx novou identitu xxxxx. Xxxxxxxxx příslušný xxxxx x xxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx x xxxxxxxxx aktualizuje xxxxxxxxx týkající se xxxxxxxx látky.
Xxxxxx 14
Xxxxxxxx xxxx xxxxxxxxx
1. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxx účastníka pro xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxxxx xxxxxxx xxxxx z těchto případů:
|
x) |
xxxxx xxxxxxx xxxxxxxxx podporující xxxxx kombinaci xxxxx x xxxx xxxxxxxxx včas xxxxxxxxxx xxxxx článku 11 x xxxxxx xxxx xxxxxxxxx xxx xxxxx kombinaci xxxxxx předtím převzata; |
|
b) |
xx xxxxxxx xxxx definice xxxxx xxxxxx 13; x xxxxx xxxxxxx xx xxxxx xxxx xxxxx té xxxxx, xx xxxxxx se vztahuje xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx xxxxxxx nová xxxxxxxx xxxxx. |
2. Xx xxxxxxxx xxxxxx xxx dne zveřejnění xxxxx odstavce 1 xxxx xxxxxxxxx osoba xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxx článku 17.
3. Xx xxxxxxxx měsíců xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx xx části 2 přílohy II podle xxxxxx 17.
Xxxxxx 15
Kombinace xxxxx x xxxx xxxxxxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxx (EU) x. 528/2012 x xx xxxxxx na xxx, xxxxxxx xx stávající xxxxxx xxxxx, xxx xxxx xxxxxxxxx ani xxxxxxxx do xxxxxxxx xxxxxxxx xxx xxxxx xxx přípravku x xxxx xxxxxxxx do xxxxxxx X uvedeného xxxxxxxx, xxxx xxxxx xxxxxxxx xxxx se x xx xxxxxx, xx xxxxxxx xxxxx xxxxxxxxx pro zařazení xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx typ xxxxxxxxx xx xxxxxxx některého x xxxxxx xxxxxx:
|
x) |
xxxxx uvádějící xxxxxxx xx xxx xx spoléhala xx xxxxxx xxxx xxxxxxx doporučení vydané Xxxxxx xxxx příslušným xxxxxxx xxxxxxxxxx v souladu x xxxxxxx 26 směrnice 98/8/XX xxxx xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, xxxxx na xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxx xxxxxxx pokyny xx doporučení k xxxxxxxxxxx, xx xxxxxxx byl xxxxx x xxxxxxxxxx směrnice 98/8/XX nebo xxxxxxxx (XX) x. 528/2012, nebo xx xxx xxxxxxxxx xxx přípravku xxxxxx x xxxxxxxxx, xxx xxxxx xxxx xxxxxx xxxxx xxxxxxxx, a xxxxx jsou xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx v xxxxxxxxxx přijatém xxxxx xx. 3 xxxx. 3 xxxxxxxx (EU) x. 528/2012 xxxx x xxxxxx, xxxxxxxxx xxxxxxxx xxxxxxxxxxxx Komisí; |
|
x) |
látka xxxxxxxxx xxxxxxxx xxx xxxxxxxxx x xxxxxx stanovené x xxxxxx 6 xxxxxxxx (XX) č. 1451/2007; |
|
c) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxxxxx xxxx přípravku, xxx xxxx xxxx xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx působnosti těchto xxxx xxxxxxxxx a obsahuje xxxxx zařazenou do programu xxxxxxxx pro původní xxx přípravku, ale xxxxxx pro xxxx. |
Xxxxxx 16
Prohlášení x xxxxx na xxxxxxxx
1. Xxxxxxxxxx x xxxxx xxxxxxx látku, xxxxx je xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxx xxxxxx 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx xx xxxxx xxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx, jednomu x následujících xxxxxxxx:
|
a) |
Xxxxxx xxxxxxxxxx xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 písm. a); |
|
b) |
agentuře nejpozději 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x čl. 15 xxxx. x); |
|
x) |
Komisi xxxxxxxxxx 30. xxxxx 2015 v xxxxxxxxx xxxxxxxxx v čl. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku. X xxxxxxxxx xxxxxxxxx x xx. 15 písm. x) xxxx xxxxxxxxxx xxxxxxxxx opodstatněné xxxxxxxxxx, x nějž xxxxxxx, xx xxxx splněny xxxxxxx podmínky v xxx xxxxxxx.
3. Xxxxx xxxx xxxxxxxxxx učiněno x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) xxxx c) x Xxxxxx dospěje xx xxxxxxxxxx x xxxxxxxxx státy x závěru, xx xxxxxxxx 6 není xxxxxxxxxx, x xxxxxxxx, xx xxxx xxxxxxx podmínky xxx xxxxxxxx xxxxxxx x xx. 15 xxxx. x), xxxxxxx o xxx xxxxxxxx.
4. Xxxxx bylo xxxxxxxxxx xxxxxxx x xxxxxxx uvedeném x xx. 15 xxxx. b) xxxx pokud Komise xxxxxxxxxxx agenturu xxxxx xxxxxxxx 3, zveřejní xxxxxxxx xxxx xxxxxxxxx elektronickými xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Pro xxxxx xxxxxx xxxxxxxx xx xxxxxxxxxx xxxxx čl. 3a xxxx. 3 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 1451/2007 xxxxxxxx za zveřejnění xxxxx tohoto odstavce.
5. Xxxxxxxxx xxxxx, xxxxx má xxxxx xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx, tak může xxxxxx xxxxx xxxxxx 17 xx xxxxx měsíců xxx xxx xxxxxxxxxx xxxxx odstavce 4.
6. V případech xxxxxxxxx x xx. 15 xxxx. x) a c) xx xxxxxxxxx látky x xxxx xxxxxxxxx považuje xx xxxxxxxxx xxxxxxxxxx x xxxx xxxxxxxxx x xxxxxxx xxxxxxxx, xxxxx xxxx xxxxxxx tyto xxxxxxxx:
|
a) |
xxxxxxxxx xxxxxx xxxxx je xxx xxxxxxxx xx xxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxxx předložená xxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxx xxx obsahuje xxxxxxx xxxxx, xxxxx xxxx xxxxxxxx xxx hodnocení xxxx přípravku; |
|
c) |
účastník, xxxxx xxxxxxxxx dotyčnou dokumentaci, xxxxx, že xx xxxxx o podporu xxxx kombinace xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Xxxxxxxx xxxxx xx. 14 odst. 2 x 3 nebo xx. 16 xxxx. 5 xx xxxxxxxxxxx agentuře prostřednictvím xxxxxxxxx.
2. Xxxxxxxx xxxx být xxxxxxxxxx ve formátu XXXXXX. Xxxx obsahovat xxxxx uvedené x xxxxxxx X.
3. Xxxxx xxxx x xxxxxxx XX pro xxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx jím xxxxxxxxx xxxxxxxxxxx orgánu, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, x xxxxxxxx xxxxxxx xxxxxxxxx dokládající, xx xxxxxxxxx xxxxx xxxxxxxx s xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x xxx xxxxxxx xxxxxxxx Xxxxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx podle nařízení (XX) x. 564/2013. Jestliže xxxxxxxxxxx xxxxxxxx xxxxxxxx xx 30 dnů xx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx x xxx oznamovatele x Komisi.
5. Xx uhrazení xxxxxxxx xxxxxxxx xx 30 dnů xxxxx, xxx oznámení xxxxxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx požadavkům xxxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxx 30 dnů, xxx své xxxxxxxx xxxxxxx nebo opravil. Xx xxxxxxxx xxxx 30xxxxx xxxxx xxxxxxxx xx 30 dnů xxx xxxxxxxx, xx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx 2, xxxx xxxxxxxx zamítne, x xxx xxxxxxxxxx xxxxx xxxxxxxxxxxx x Xxxxxx.
6. X xxxxxxx x xxxxxxx 77 nařízení (XX) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 xxxx 5 podat xxxxxxx xxxxxxxxxx.
7. Xxxxx oznámení xxxxxxxx xxxxxxxxxx podle xxxxxxxx 5:
|
a) |
v xxxxxxx, že bylo xxxxxxxx předloženo podle xx. 14 odst. 2 xxxx 3, xxxxxxxx neprodleně xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx a xxxxxxxx identity látky; |
|
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx xxxxx xx. 16 xxxx. 5, xxxxxxxx neprodleně xxxxxxxxx Komisi, xx xxxxxxxxxx xxxx vyhověno. |
Xxxxxx 18
Xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxx za xxxxxxxxx x xxxxxxx s čl. 16 xxxx. 6 xxxx pokud xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxxx xxxxxxxxx x xxxxxxx x xx. 17 xxxx. 7 písm. b), xxxxxx Xxxxxx kombinaci xxxxx x xxxx přípravku xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, které nejsou xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxx xxxxxx xx xxxxx xxxxxxxxx x xx. 16 xxxx. 5 xxxxxxxx xxxxx xxxxxxxx xxxx xxxxx xxxx xxxxxxxx xxxxxxx ve xxxxxxxx xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5, xxxxxxxx o tom xxxxxxxxx xxxxxxx státy xxxxxxxxxxxxxxx xxxxxxxxx a zveřejní xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Rozhodnutí Xxxxxx x xxxxxxx, které xxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx xxxxxxxx návrh xxxxxxxxxx o xxxxxxxxxxx xxxxx xx. 89 odst. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx čl. 12 xxxx. 3 tohoto xxxxxxxx; |
|
x) |
pokud xxxxx xxxxx xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxx x xx. 14 xxxx. 2 nebo 3 tohoto nařízení xxxx pokud bylo xxxxxxxx xxxxxxxxxx a zamítnuto xxxxx xx. 17 odst. 4 xxxx 5; |
|
x) |
xxxxx xxxx xxxxxxxx předloženo xx xxxxx xxxxxxxxx x xx. 14 odst. 2 xxxx 3 tohoto xxxxxxxx x xxxx dodrženy xxxxxxxxx podle xx. 17 xxxx. 5 tohoto nařízení, xxx xxxxxxxx látky x xxxxxxxx xxxxxxxx pouze xxxx xxxxxxxxx identity x xxxxxxx XX xxxxxx nařízení. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. c) xx xxxxx rozhodnutí x xxxxxxxxxxx vztahuje xx xxxxxx látku, na kterou xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx x schválení.
KAPITOLA 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx pro xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo xxxxx xxxxxxxx na trh x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. x) a x), xxxx xxxxx xxxxxxxx xxxx z xx vzniká. X xxxxxx případech:
|
a) |
nesmí být xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx xxxxxx tohoto xxxxxxxx v platnost; |
|
b) |
stávající xxxxxx xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 xxxxxx xx xxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx praxe dodávání xx&xxxx;xxx a používání biocidního xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx v xx. 15 xxxx. x), xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. V xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx přípravek xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xx z xxxx xxxxxxxxx událostí, xxxxx xxxxxxx xxxxxxx:
|
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx přípravku xxxxx xxx dále xxxxxxxxx xx&xxxx;30 měsíců xx xx z xxxx xxxxxxxxx xxxxxxxx, xxxxx nastane později:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx stát xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx na trh x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx účinné xxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 xxxx. 4 pro xxxxxxxxx xxx xxxxxxx, xxxx xxxxx xxxxxxxx xxxx x xx vzniká. X těchto xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx, kdy xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx článku 19 x |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx xxxx využívány xx&xxxx;xxxxxxxx xxxxxx xx xxxx xxxxxxxxx xxxxxxxxxx. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx xx. 55 xxxx. 1 xxxxxxxx (XX) x. 528/2012, do osmnácti xxxxxx xx xxxx xxxxxxxxxx o neschválení xxxxxxxxx účinné látky, xxxxx xxxxxxx xxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx uvedených x xx. 5 xxxx. 2 xxxxxx pododstavci xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxxx xxxx může předložit Xxxxxx odůvodněnou xxxxxx x xxxxxxxx xx xx. 89 odst. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx stát xxxxxxxx odůvodněnou xxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxxxx obsahuje xxxxxxx informace, xxxxxxxx xxxxxxx stát musí xxxxxxx předložit nedůvěrné xxxxx.
3. Xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxx elektronickými xxxxxxxxxx. Xxxxxxx státy xxxx xxxx xxxxx xxxxx xxxxx xxxxxxxxxx xx xxxxx 60 xxx po xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxx Komise xxxxxxx odchylku xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 528/2012, xxxxx umožní xxxxxx xxxxxxxx přípravky, jež xxxxxxxxx x xxxx xxxxx, xxxxxxxx ji xxxx x xx xxxxxxxx, xx trh xxxxxxxxxx xxxxxxxxx státu x xxxxxxxx xx x xxxxx xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx právními předpisy x x xxxxxxxx xxxxxxxx xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx Komisí.
5. Členský xxxx, xxxxx xx xxxxxxxx odchylka:
|
x) |
xxxxxxx, xx xxxxx xxxxxxxxx xxxx omezeno xx xxxxxx případy x xxxxxxx xxxx, xxx xxxx xxxxxx xxxxxxxx xxxxxxxx 1; |
|
x) |
xxxxxx xxxxxx opatření xx xxxxxxxx xxxxx, aby xxxxxxxx minimalizaci xxxxxxxx xxxxxxx, zvířat nebo xxxxxxxxx xxxxxxxxx; |
|
x) |
xxxxxxx, aby xx xxxxxxx xxxxxxxxxxxx xxxxxx nebo aby xxxx xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx žádost x xxxxxxxxx xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) č. 528/2012. |
KAPITOLA 5
ZÁVĚREČNÁ XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx xx xxxxxxxx (XX) x. 1451/2007.
Odkazy xx xxxxxxx xxxxxxxx xx xxxxxxxx xx xxxxxx na xxxx xxxxxxxx.
Xxxxxx 24
Xxxxx x xxxxxxxx
Xxxx nařízení vstupuje x xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.
Xxxx nařízení je xxxxxxx x celém xxxxxxx a xxxxx xxxxxxxxxx ve všech xxxxxxxxx xxxxxxx.
X Xxxxxxx xxx 4. xxxxx 2014.
Xx Xxxxxx
xxxxxxxx
José Manuel XXXXXXX
(1) Úř. xxxx. L 167, 27.6.2012, s. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Xxxxxx (ES) x. 1451/2007 ze xxx 4. xxxxxxxx 2007 o xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 odst. 2 xxxxxxxx Evropského xxxxxxxxxx x Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx přípravků na xxx (Xx. xxxx. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady 98/8/XX xx xxx 16. xxxxx 1998 x xxxxxxx biocidních xxxxxxxxx xx xxx (Xx. xxxx. X 123, 24.4.1998, x. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Soudního xxxxx (xxxxxxx xxxxxx) xx xxx 1. xxxxxx 2012 (xxxxxx o xxxxxxxxxx x xxxxxxxxx xxxxxx: Landgericht Xxxxxxx – Xxxxxxx) – Xöxx XxxX xxxxx Xxxxx XxxX (uvádění xxxxxxxxxx přípravků xx xxx – směrnice 98/8/XX – xx. 2 odst. 1 xxxx. x) – xxxxx „xxxxxxxx xxxxxxxxx“ – xxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx je xxxx, xxxxxxxx xxxx xxxxxxxxxxx), C-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx xxxxxxx xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (EU) x.&xxxx;528/2012 o dodávání xxxxxxxxxx xxxxxxxxx na xxx x&xxxx;xxxxxx xxxxxxxxx (Xx. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x změně x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/ES x x xxxxx xxxxxxxx (XX) č. 1907/2006 (Xx. věst. X&xxxx;353, 31.12.2008, s. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) č. 564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx xxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh x&xxxx;xxxxxx xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1907/2006 ze xxx 18. xxxxxxxx 2006 x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Evropské xxxxxxxx xxx chemické xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x zrušení xxxxxxxx Xxxx (EHS) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX a xxxxxxx Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/ES x 2000/21/XX (Xx. věst. X 396, 30.12.2006, x. 1).
XXXXXXX X
Xxxxxxxxx požadované xxx oznámení xxxxx xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
|
1) |
xxxxx, xx xxxxx xx xxxxxxxxx xxxxxxx xxxxxx ve smyslu xx. 3 xxxx. 1 xxxx. x) xxxxxxxx (XX) č. 528/2012; |
|
2) |
údaje x xxxx/xxxxxx xxxxxxxxx, xx xxxxx/x se xxxxxxxx xxxxxxxx; |
|
3) |
xxxxxxxxx x xxxxx xxxxxxxx, xxxxx xxxx xxxxxx xxx účely xxxxxxx x xxxxxxxxx xx xxxxxxxx xx xxxxxxx X xxxxxxxx (EU) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
|
4) |
xxxxxxxxx xxxxxxx v xxxxxxxx
|
|
5) |
xxxxx xxxx xxxx oznámení xxxxxxx x xxxxxxx uvedeném x xx. 15 písm. a), xxxxx, xx xxxxx xxxx xx xxxx xxxx xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxxxxx xxxx zveřejnění rozhodnutí xxxx xxxxxx uvedených xx xxxxxxxx písmenu. |
XXXXXXX XX
XXXXXXXXX XXXXX X XXXX XXXXXXXXX ZAŘAZENÉ XX XXXXXXXX XXXXXXXX XXX 4. XXXXX 2014
ČÁST 1
Xxxxxxxxx účinné látky x xxxx xxxxxxxxx xxxxxxxxxxx xx dni 4. xxxxx 2014, s výjimkou xxxxxxxxxx jiných xxxxxxxxxxxxx xxx xxxx, které xxxx xxxxxxxx xxxxxxx x xxxxxxxxx 1017 x 1019.
|
Číslo xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx ES |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
kyselina xxxxxxxxxx |
XX |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
propan-1-ol |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
xxxxxxxx xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx kyselina/2-hydroxyethanová kyselina |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
kyselina xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (xxxxxxx) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
symklosen |
UK |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (xxxxxxxxxxxxx) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
chlorofen |
N |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(natrium-kakodylát) – natrium-dimethylarsinát |
PT |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (sodná xxx xxxxxxxxxxxxxxx – chloramin X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
kalium-dimethyldithiokarbamát |
UK |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
XX |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
ES |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
xxxxxx |
DK |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
karbamonitril |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (dazomet) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx měďný |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx vápno/hašené xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx vápenatý/vápno/pálené xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx měďný |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
butan-2-on-peroxid |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
natrium-dichlorisokyanurát xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (MES) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
xxxxxxxxx |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (reakční xxxxxxxx xxxxxxxxxxxxxx a xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx (pyrithion sodný) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (HHT) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (XXXX) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
IT |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
stříbro |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
xxx |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
oxid xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
peroxid xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (EDHO) |
XX |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
dusičnan xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
xxxxx xxxxxx |
UK |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
ES |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
xxxx xxxxxxxxxx |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx xxxxxx |
SE |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
xxxx-1-xxx-1λ5-xxxxxxx-2-xxxxxxx |
SE |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
dodecylguanidin-monohydrochlorid |
ES |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
brommonochlorid |
XX |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(benzyloxy)methanol |
UK |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx xxxxxxx (xxxxxxxxx mědi) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
UK |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (xxxxxx xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (HPT) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (XXX) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
ES |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]imidazol (imazalil) |
DE |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (DBDCB) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
cis- a xxxxx-x-xxxxxxx-3,8-xxxx (směs) (citriodiol) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-xxxxxxx-2-xxxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (THPS) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-dichlorfenyl)-4-propyl- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx kokosového xxxxx (XXXXX/XXXX) |
IT |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
N |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
IT |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
alkyl(C12-18)dimethylbenzylammoniumchlorid (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
alkyl(C12-16)dimethylbenzylammoniumchlorid (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (DDAC) (X8-10) |
IT |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
natrium-N-(hydroxymethyl)glycinát |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
alkyl(C10-C16)dimethylaminoxidy |
PT |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx hexahydrát (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
xxxxxxx, Xxxxxxxxxxx xxxxxx, xxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (C12-C14)) |
IT |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxx (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxx |
ES |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
xxxxxxxxx zvrhlá, Xxxxxxxxx xxxxxxx, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
reakční xxxxxxxx xxxxxxxxx kyseliny x X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-ftalimidoperoxyhexanová kyselina (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
CZ |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
xxxxxxx tetrachlordekaoxidu (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
SE |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-xxxxxxxxxx (xxxx stereoisomerů) (imiprothrin) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Xxxxxxxx xxxxxxxxxx 2362, xxxx ABTS-1743 |
XX |
mikroorganismus |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Bacillus xxxxxxxxxxxxx xxxxx. xxxxxxxxxxx, xxxx SA3A |
XX |
mikroorganismus |
xxxx relevantní |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) x 2-methylisothiazol-3(2H)-on (Xxxxxx 220-239-6), směs (3:1) (xxxx XXXX/XXX) |
XX |
xxxx |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
xxxxxxx xxxxx (vyráběný xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxx in xxxx) |
XX |
xxxx |
xxxx relevantní |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx kyselina |
FR |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
SE |
není relevantní |
není xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx reakce x xxxxxxxxxxxx kyselinou (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx xxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx s xxxxxx a xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
reakční xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
xxxxxxx produkty 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx s chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx x xxxxxxx xxxxxxx |
XX |
xxxx k dispozici |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx zeolit |
XX |
není x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx oxidu xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx agregátu x primárními xxxxxxxxx xx xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (jako xxxxxxxxxxxx tvořený xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
křemelina |
FR |
xxxxxxxxx na xxxxxxx rostlin |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 xxxxxxx 1X xxxxx, 1X: 1R xxxxx, 1X: 1X xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (směs 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
přípravek xx ochranu xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
polymer X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (EINECS 203-439-8)/xxxxxxxxx xxxxxxxxx xxxxxxx xxxxxx (XX Xxxxxxx) |
XX |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
FR |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(didecylmethylamonio)ethyl]-ω-[hydroxypoly(oxyethylen)-propionát] (Xxxxxx 26) |
IT |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (polymerický betain) |
XX |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx nepodporované xx dni 4. xxxxx 2014
Xxxx část xxxx xxxxxxx xxxxxxxx
|
— |
xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxx x xxxxxxx níže, xxxxxx xxxxxxxxxx nanoforem, |
|
— |
xxxxxxxx xxxxxxxxx xxxxx kombinací xxxxx a typu přípravku xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, xxxxx xxxx xxxxxxx x xxxxxxx, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx látek x xxxx xxxxxxxxx schválených xx 4. srpna 2014, x xxxxxxxx xxxx, které xxxx výslovně xxxxxxxxx. |
Xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxx xx xxxx části xxxxx předmětem xxxxxxxxxx x neschválení xxxxx xxxxxx 20, xxxxxxxx xxxxx xxxxx nepodá xxxxxxxx xx xxxxxxxx xxxxxx xx vstupu xxxxxx xxxxxxxx v platnost xxxxx xx. 14 odst. 3 xxxx xxxxx xx takové xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5.
|
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Členský xxxx xxxxxxxxx |
Xxxxx ES |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (nově xxxxxxxxxx xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
benzyl(hexadecyl)dimethylamonium-chlorid (xxx položka 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
benzyl(dimethyl)tetradecylamonium-chlorid (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx položka 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (viz xxxxxxx 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
síran xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx stříbrný |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
UK |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-fenoxybenzyl(1RS,3RS;1RS,3SR)-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropankarboxylát (permethrin) |
IE |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
alkyl(benzyl)dimethylamonium-chloridy (xxxxx odvozen xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx oleje) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od xxxxxxxxxxxxxxx xxxxxxxx kyselin xxxx) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
alkyl(C8-C16)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
alkyl(C10-C16)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
alkyl(C10-C16)dimethylaminoxidy |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
dialkyl(C8-C18)dimetylamonium-chloridy (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
dihydrogen-bis(monoperoxyftalato)magnesát xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx z xxxxx xxxxxxxx Xxxxxxxxxxx indica xxxxxxxxxxx vodou x xxxx xxxxxxxxxx organickými xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (nově xxxxxxxxxx xxxxx položky 777) |
NL |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx xxxxxxxx-xxxxxxx, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x xxxxxxxxx vodíku (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(dialkyl)dimethylamonium-chloridy, -bromidy xxxx -methyl-sulfáty) (alkyly (X6-X18) nasycené x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx kyselin xxxx, xxxxxxxxxx oleje x xxxxxxxx xxxxx) (DDAC) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) xxxxxxxx x nenasycené, odvozené xx xxxxxxxx kyselin xxxx, kokosového xxxxx x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx uvedených x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (alkyly (X8-X22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx mastných xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx látek xxxxxxxxx x xxxxxxx EINECS |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
xxxx relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx položku 671) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx xxxxxxxxx xxx položku 667) |
IT |
není xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx položku 725) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx položku 724) |
XX |
xxxx relevantní |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
xxxxxxxxxxxxxx xxxx obsahující stříbro, xxxxx, xxxxxx x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 673) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (alkyl xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxxx než xxxxx xxxxxxxxx xxx položku 635) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, stříbrný a xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx technický) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx xxxxxxxxx |
Xxxxx pro xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx čl. 6 xxxx. 3 xxxx. x) |
Xxxxx pro xxxxxxxx xxxxxxxx xxxxxxxxxx podle xx. 7 xxxx. 2 písm. b) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 x 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 x 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |